TransCode Therapeutics Inc (RNAZ) Quote

The scientific nobel management community conveniently fucked investors all their careers

Another Proxy that they conveniently now state Shareholders of record on 12/17/24:

To approve, (i) for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of Common Stock by the Company upon exercise of the Series C Warrants and the Series D Warrants (both as defined in this Proxy Statement), (ii) a series of adjustments to the exercise price of the Warrants and an increase in the underlying Common Stock of the Warrants, (iii) an alternative cashless exercise feature in the Series D Warrants and (iv) an adjustment to the exercise price and number of Warrants upon the Shareholder Approval Date (as defined in the Proxy Statement) and possibly at other times, subject to a floor price of $2.4882 (the “Issuance Proposal” or “Proposal 1”);

When this one flys will be dollars. 

FDA approval .001 coming

Buying opportunity most of float exchanged yesterday 

Rnaz.  Incredible update

Go. Rnaz. 

An upside down piece of shit garbage runned by professional peddlers scam artists of the scientific nobel community

H.C. Wainwright is a short piece of shit, They screwed everyone and everything since inception bastards

The shorts in bed with management and big pharma to sabotage and destroy the cure to cancer

It’s a piece of short garbage in bed with all of management to sabotage and destroy shareholders

Go. RNAZ.  Incredible results

Monk you must have some major screens you look at all day 

12/18/24 03:06PM Transcode Therapeutics Inc : H.C. Wainwright adjusts PT to $20 from $3 after reverse stock split 

Good luck I will clean them up I wish I wasn't limited to 10 k and 5k buys

With them selling more shares again as per the Form D effect notice, the shorts pounded this down today and will continue. That's what will keep happening. They thought they would be getting shares going higher with today's PR but they just don't understand how the market works. I will wait to pick up another 500,000 shares when it goes back down to the $.20 mark like it probably will in the coming weeks. Very sad.

RNAZ, new 52 week low

Taking my chances at 10 cents a share presplit

Absolutely, these motherfuckers in management have been fucking investors up the ass all their careers , The nobel prize rna clinical trials is the scam of century

Founders and all of management in bed with the shorts to destroy all shareholders value

Yes then another reversal 10:1 Till they rob you blind

Nice pick up day shorts should have covered float almost picked off

Holy chit, what a disaster..how are they allowed to do this again so quickly?

Nice!  The float will be down to 10 shares!

Tomorrow morning 200:1

When is the next reverse split?

It’s the piece of shit of the scientific nobel community, burn this scam to the ground wilth all of management filling up their pockets

It’s official RNAZ is a scam of the scientific nobel community , Management loves to collapse this piece of garbage while they funnel money in their pockets for christmas bonus

The scientific nobel community is broke , they are completely useless in all aspects of business

Shorts still ruling for sure 

Results not bad 66% inhibition after 24 hours. 

The Scientific nobel clinical trial garbage can exploded upsidedown, fill up your pockets fitzgerald and all of the scammers in management christmas bonus is here

Go on shorties burn this garbage to the ground , it was managements plan from the beginning to siphon investors money

RNAZ The biggest scammers of the scientific community

News is out and it’s a piece of garbage of the scientific community, shame on you management for being in bed with all the shorts

RNAZ is the biggest disgrace of the nobel scientific community,

News is out and it collapses
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
December 18 2024 - 8:00AM
PR Newswire (US)

Share On Facebook
Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2

No significant safety or dose limiting toxicities reported in Cohort 2
New patients currently being evaluated for eligibility in Cohort 3
PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results

BOSTON, Dec. 18, 2024 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critical to the emergence and progression of many metastatic cancers. The dose administered to the third cohort will be approximately double the dose administered to the second cohort.

Logo


Several patients in the first and second cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. Analysis of Cohort 1 data for pharmacokinetic (PK) and pharmacodynamic (PD) activity is ongoing and to date suggests that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from the previous Phase 0 clinical trial. Specifically, results from Cohort 1 confirmed the Phase 0 observation that TTX-MC138 shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion. Additionally, the concentration of TTX-MC138 in blood plasma as a function of dose in humans was found to be higher than achieved in nonclinical studies, suggesting a favorable pharmacokinetic profile.

"An SRC is a group of clinicians and experts that oversee patient safety during the conduct of a clinical trial. The SRC determines whether and how a study should proceed, including dose escalation and de-escalation decisions in accordance with the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated," commented Sue Duggan, TransCode's Senior Vice President of Operations. Duggan added, "Enrollment into the study continues based on the cumulative safety data review. Eligible patients may now be screened and scheduled in Cohort 3 for treatment with the next dose level of TTX-MC138 while preliminary data analysis continues."

News coming soon they tanking it adds at $4.70s 

In best best interest to destroy shareholders and fill up his pockets for christmas bonus

Will be sub-dollar and then soon another Reverse Split will be proposed again by this shady CEO and call it again "In the Best interests of the shareholders "....

Looking better $6s just about.18 cents add a few. Market cap collapsing

RNAZ, new 52=week low

Great job dudes!! Management 8M Year end bonus for christmas, Job well done

Nobel prize and all the scientific community didn’t even acknowledge the existence of this nobel prize clinical scam

It was a planned sabotage from the start, Master Dudley screwed all shareholders and passed the torch to the biggest scumbag rat CFO cook the books fill up his pockets Fitzgerald

$150,000 a share IPO in 2022 to record low $6.75 congrats to all longs congrats to all of management

Micro rna nobel scientific broke community is the scam of the century

Management all going to jail for fraud

Where are you hiding you dirty rat cunt CSO Zdravka Medarova, you disappeared and fucked in vestors all your career you dirty whore

Buy some shares on the open market you broke bitch dirty cunt Zdravka Medarova you love to screw investors and fill up your Louis Vuitton purse while you fuck all your shareholders up the ass you dirty whore crack head bitch